Cover Image

GAS2L1 is a potential biomarker of circulating tumor cells in pancreatic cancer

Pancreatic cancer is a malignant disease with high mortality and a dismal prognosis. Circulating tumor cell (CTC) detection and characterization have emerged as essential techniques for early detection, prognostication, and liquid biopsy in many solid malignancies. Unfortunately, due to the low EPCA...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhu, Lei (Author) , Kan, Kejia (Author) , Grün, Johanna L. (Author) , Hissa, Barbara (Author) , Yang, Cui (Author) , Győrffy, Balázs (Author) , Loges, Sonja (Author) , Reißfelder, Christoph (Author) , Schölch, Sebastian (Author)
Format: Article (Journal)
Language:English
Published: 15 December 2020
In: Cancers
Year: 2020, Volume: 12, Issue: 12, Pages: 1-16
ISSN:2072-6694
DOI:10.3390/cancers12123774
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers12123774
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/12/12/3774
Get full text
Author Notes:Lei Zhu, Ke-Jia Kan, Johanna L. Grün, Barbara Hissa, Cui Yang, Balázs Győrffy, Sonja Loges, Christoph Reißfelder and Sebastian Schölch
Description
Summary:Pancreatic cancer is a malignant disease with high mortality and a dismal prognosis. Circulating tumor cell (CTC) detection and characterization have emerged as essential techniques for early detection, prognostication, and liquid biopsy in many solid malignancies. Unfortunately, due to the low EPCAM expression in pancreatic cancer CTCs, no specific marker is available to identify and isolate this rare cell population. This study analyzed single-cell RNA sequencing profiles of pancreatic CTCs from a genetically engineered mouse model (GEMM) and pancreatic cancer patients. Through dimensionality reduction analysis, murine pancreatic CTCs were grouped into three clusters with different biological functions. CLIC4 and GAS2L1 were shown to be overexpressed in pancreatic CTCs in comparison with peripheral blood mononuclear cells (PBMCs). Further analyses of PBMCs and RNA-sequencing datasets of enriched pancreatic CTCs were used to validate the overexpression of GAS2L1 in pancreatic CTCs. A combinatorial approach using both GAS2L1 and EPCAM expression leads to an increased detection rate of CTCs in PDAC in both GEMM and patient samples. GAS2L1 is thus proposed as a novel biomarker of pancreatic cancer CTCs.
Item Description:Gesehen am 09.02.2022
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers12123774

Similar Items